Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort

Joanne M Carson; Behzad Hajarizadeh; Josh Hanson; James O'Beirne; David Iser; Phillip Read; Anne Balcomb; Jane Davies; Joseph S Doyle; Jasmine Yee; Marianne Martinello; Philippa Marks; Gregory J Dore; Gail V Matthews

doi:10.1016/j.drugpo.2021.103422

Back

Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort

Journal article

Peer reviewed

Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort

Joanne M Carson, Behzad Hajarizadeh, Josh Hanson, James O'Beirne, David Iser, Phillip Read, Anne Balcomb, Jane Davies, Joseph S Doyle, Jasmine Yee, …

International Journal of Drug Policy, Vol.96, pp.1-5

2021

DOI: https://doi.org/10.1016/j.drugpo.2021.103422

Files and links (1)

url

https://doi.org/10.1016/j.drugpo.2021.103422View

Accepted Version

Abstract

Hepatitis C

HIV

injecting drug use

prison

reinfection

Background: Direct acting antiviral (DAA) therapy is highly effective for hepatitis C virus (HCV) infection, but reinfection following treatment may compromise benefits of cure. This study assessed the real-world effectiveness of treatment for reinfection. Methods: Real-world effectiveness of antiviral therapy in chronic hepatitis C (REACH-C) is an observational study evaluating treatment outcomes following sequential DAA initiations across 33 health services in Australia between March 2016-June 2019. Reinfection was defined by post-treatment genotype switch or HCV viraemia after sustained virologic response (SVR12). Results: Of the 10,843 individuals initiating DAA therapy post-treatment viraemia was reported in 526 of whom 99 were reinfections. Treatment for reinfection occurred in 88 individuals. In those with available treatment outcomes, SVR12 was similar to initial treatment in the overall REACH-C cohort (95% vs 95%; p = 0.745) and comparable across primary, tertiary, and prison settings. Classifying unknown treatment outcomes as failures, SVR12 for treatment of reinfection was lower than initial treatment in REACH-C (67% vs 81%; p = 0.002), due to higher lost to follow-up. Conclusions: Treatment of reinfection is highly effective and can be delivered in non-specialist settings. Access to treatment for reinfection in high-risk populations is crucial to HCV elimination.

Details

Title: Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort
Authors: Joanne M Carson (Author) - UNSW Sydney
Behzad Hajarizadeh (Author) - UNSW Sydney
Josh Hanson (Author) - UNSW Sydney
James O'Beirne (Author) - University of the Sunshine Coast
David Iser (Author) - Scope Gastroenterology (Melbourne, VIC)
Phillip Read (Author) - Kirketon Road Centre
Anne Balcomb (Author) - Prince Street Medical
Jane Davies (Author) - Menzies School of Health Research
Joseph S Doyle (Author) - Burnet Institute
Jasmine Yee (Author) - UNSW Sydney
Marianne Martinello (Author) - UNSW Sydney
Philippa Marks (Author) - UNSW Sydney
Gregory J Dore (Author) - UNSW Sydney
Gail V Matthews (Author) - UNSW Sydney
Publication details: International Journal of Drug Policy, Vol.96, pp.1-5
Publisher: Elsevier BV
Date published: 2021
DOI: 10.1016/j.drugpo.2021.103422
ISSN: 1873-4758
Organisation Unit: University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99570206902621
Output Type: Journal article

Metrics

24 Record Views

18 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Web Of Science research areas: Substance Abuse

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites